Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HZ/su co-administration with Pneumovax 23 in adults aged 50 years and older
2012-005314-19Phase 3Completed
- Sponsor
- GSK
- Start
- Dec 2013
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Zoster vaccine recombinant and 23-valent pneumococcal polysaccharide vaccine in herpes zoster (HZ) and pneumococcal disease (2 arms), sponsored by GSK. Primary endpoint: HZ/su vaccine response rate. Started Dec 2013; status: completed.
02
Drugs
Zoster vaccine recombinant23-valent pneumococcal polysaccharide vaccine
03
Conditions
herpes zoster (HZ)pneumococcal disease
Beyond the preview
Go deeper on 2012-005314-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-005314-19.